Esperion Therapeutics (ESPR) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ESPR · Stock Price

USD 3.14+2.34 (+292.50%)

Market Cap: $808.3M

Historical price data

Market Cap: $808.3MPipeline: 22 drugs (7 Phase 3)Patents: 20Founded: 1998Employees: 100-250HQ: Ann Arbor, United States

Sector Ranking#192 in Small Molecule Drugs

Overview

Esperion Therapeutics' mission is to deliver oral, once-daily, non-statin medicines for patients with elevated LDL-C. Its key achievement is the successful FDA approval and commercialization of bempedoic acid (NEXLETOL) and its combination with ezetimibe (NEXLIZET), establishing a new therapeutic class. The company's strategy combines direct U.S. commercialization with ex-U.S. partnerships to maximize global reach while advancing a pipeline of next-generation lipid-modifying agents. Esperion aims to become a leading cardiometabolic company by addressing broader patient populations and complementary risk factors.

CardiovascularMetabolic Disorders

Technology Platform

Liver-targeted prodrug platform centered on ATP citrate lyase (ACL) inhibition, utilizing a liver-specific activation mechanism to reduce LDL-cholesterol synthesis with a favorable muscle safety profile.

Pipeline

22

22 drugs in pipeline7 in Phase 3

Drug	Indication	Stage
Bempedoic Acid / Ezetimibe Oral Tablet + Placebo	Cardiovascular Diseases	Approved
Bempedoic Acid 180 MG Oral Tablet + Bempedoic Acid/Ezetimibe...	Healthy Lactating Women	Approved
Bempedoic acid + Ezetimibe	Hypercholesterolemia	Phase 3
bempedoic acid	Hypercholesterolemia	Phase 3
Bempedoic Acid + Ezetimibe + Placebos	Hyperlipidemias	Phase 3

FDA Approved Drugs

2

NEXLIZETNDAFeb 26, 2020

NEXLETOLNDAFeb 21, 2020

Opportunities

The positive cardiovascular outcomes data from the CLEAR Outcomes trial enables a significant label expansion into primary prevention and strengthens the value proposition globally.

The large, persistent population of statin-intolerant patients and those not at goal on current therapy represents a durable, multi-billion dollar addressable market for convenient oral therapy.

Risk Factors

Commercial success is challenged by intense competition from generic statins/ezetimibe and injectable PCSK9 inhibitors, alongside ongoing pricing and reimbursement pressures.

The company's path to profitability depends on accelerating prescription growth and managing cash burn, with failure risking the need for dilutive financing.

Competitive Landscape

Esperion competes in a stratified market against low-cost generic statins/ezetimibe and potent, injectable PCSK9 inhibitors. Its key differentiators are oral convenience, a demonstrated cardiovascular outcomes benefit, and a muscle-friendly safety profile, positioning it as a preferred adjunctive or alternative therapy for statin-intolerant, high-risk patients.